KPV is an investigational peptide with no approved human dose. The figures below are commonly reported research and community schemas — not medically established, and all published efficacy data for KPV are preclinical. This page is educational, not a protocol.
Where the numbers come from
There is no established human dose of KPV, and the community figures that circulate do not trace back to any published study. Answering "how much KPV" honestly means separating two things that get conflated: the amounts used in the papers, which are rodent concentrations delivered into the gut, and the amounts quoted in vendor and forum material, which are milligram-scale injection figures with no citation behind them.
The doses that are actually published
In the study that established KPV's anti-inflammatory effect in animals (Dalmasso et al., Gastroenterology, 2008; PMID 18061177), KPV was administered to mice in drinking water across DSS- and TNBS-induced colitis. In the cell work supporting it, the active concentrations were nanomolar in the culture medium surrounding human intestinal epithelial and Jurkat T cells. Those are the two kinds of numbers the KPV literature contains: a concentration in water that a mouse drank, and a concentration in a dish.
Neither is a dose in the clinical sense. A drinking-water concentration depends on how much a mouse drinks; a culture concentration is what the cell sees, not what an organism absorbs. Converting either into human milligrams requires pharmacokinetic data — absorption, distribution, half-life, clearance — that has never been generated for KPV in people.
The follow-up murine work (PMID 27458604) added a constraint rather than a number: KPV's protective effect vanished in PepT1-deficient mice. Dose is not the only variable that determines whether KPV does anything — whether the transporter is present at the target tissue matters at least as much.
The commonly reported community schema
Frequently reported schemas in peptide-community discussion, all anecdotal and uncited:
- Roughly 200–500 mcg per day, described for subcutaneous or oral use.
- Short runs of a few weeks rather than continuous use.
- Start-low framing, on general caution rather than any published dose-response curve.
No published study supports these figures, and no source that quotes them names one. They describe what people report doing, which is a different claim from what has been studied.
Routes, and why researchers keep engineering them
KPV is a three-residue peptide, small and relatively stable, and it has been delivered several ways in research — but almost never as a plain systemic injection.
- Oral / gut-targeted. The route behind all the positive colitis data, exploiting PepT1 upregulation in inflamed colon. Later work went further, building hyaluronic-acid-functionalized nanoparticles specifically to carry orally administered KPV to inflamed intestinal tissue (PMID 28143741).
- Local / mucosal. A temperature-sensitive mucoadhesive hydrogel was developed to hold KPV against the tissue in chemotherapy-induced oral mucositis models (PMID 34846053).
- Subcutaneous injection. The dominant route in community use and the one with no supporting efficacy literature. Supplied as lyophilized powder, the delivered amount depends on how much diluent is added — syringe units measure volume, not milligrams.
The recurring theme in the published work is containment: keep the peptide at the tissue you want it to act on. Systemic injection is the design these groups spent years working around.
What a clinician adds that a number cannot
With no approved label, there is no established dose, no monitoring standard, and no verified product to dose from. There is also a mechanistic reason supervision matters here specifically: KPV's action is suppression of NF-κB signaling (PMID 22837805), a pathway central to host defense, and nothing published describes what sustained systemic suppression looks like in a person. The commonly reported numbers above are context for reading the literature, not a schedule.